Fibroblast Growth Factor 21 Mediates Glycemic Regulation by Hepatic JNK

• Hepatic JNK activity regulates FGF21 expression during fasting/feeding cycles
• Hepatic JNK suppresses circulating FGF21 and promotes metabolic syndrome
• Hepatocyte FGF21 is required for the effects of hepatic JNK on metabolic syndrome

SummaryThe cJun NH2-terminal kinase (JNK)-signaling pathway is implicated in metabolic syndrome, including dysregulated blood glucose concentration and insulin resistance. Fibroblast growth factor 21 (FGF21) is a target of the hepatic JNK-signaling pathway and may contribute to the regulation of glycemia. To test the role of FGF21, we established mice with selective ablation of the Fgf21 gene in hepatocytes. FGF21 deficiency in the liver caused marked loss of FGF21 protein circulating in the blood. Moreover, the protective effects of hepatic JNK deficiency to suppress metabolic syndrome in high-fat diet-fed mice were not observed in mice with hepatocyte-specific FGF21 deficiency, including reduced blood glucose concentration and reduced intolerance to glucose and insulin. Furthermore, we show that JNK contributes to the regulation of hepatic FGF21 expression during fasting/feeding cycles. These data demonstrate that the hepatokine FGF21 is a key mediator of JNK-regulated metabolic syndrome.

Graphical AbstractFigure optionsDownload as PowerPoint slide